surmount-1 tirzepatide (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants SURMOUNT-1: Adults achieve weight loss

While it may not be as widely recognized as nausea or diarrhea, feeling cold can still be an uncomfortable and concerning symptom for those who experience it

Rx is derived from the Latin word recipe (meaning to take), and it has become a universal symbol indicating a medical prescription

Importante: La semaglutida est contraindicada en pacientes con antecedentes personales o familiares de carcinoma medular de tiroides o sndrome de neoplasia endocrina mltiple tipo 2 (MEN2), y no debe usarse durante el embarazo

10.1111/j.1524-4741.2009.00855.x 54 InzucchiS

This third receptor is what gives retatrutide its edge in weight loss outcomes , driving results that exceed what dual agonists can achieve alone